BBI Solutions has launched a new Jo-1 human chimeric antibody for use as a calibrator or positive control in assays to diagnose conditions such as connective tissue disease (CTD).
BBI has used cell culture technologies in response to the concerning situation, as hospital visits continue to be dominated by Covid-19-related cases, leading to a drop in supplies of positive patient materials for certain markers, which are commonly used for calibrators and controls in IVD assays.
Autoantibodies against the aminoacyl-tRNA synthetase Jo-1 can be found in up to 20% of patients with idiopathic inflammatory myopathies (IIM), a sub-form of CTD. Jo-1 is therefore the most prevalent marker found in IIM.
Anti-synthetase autoantibodies, such as Jo-1 autoantibodies, are also strongly associated with interstitial lung disease (ILD) which makes an early diagnosis on a component level even more important.
It is the only commercially available Jo-1 human chimeric monoclonal antibody available on the market and will help companies which manufacture diagnostic tests provide physicians with the most reliable tests on the market.
Mario Gualano, CEO of The BBI Group, said: “The introduction of Jo-1 HumAb IgG further strengthens our wide portfolio of CTD products in our autoimmune range. This product will help support IVD companies to realise the growth in the autoimmune diagnostic testing market.”